Sana Biotechnology, Inc. - 8-K Filing
Sana Biotechnology reported Q1 2026 cash of $101.1M and a pro forma balance of $128.9M after securing ~$25M from Mayo Clinic's equity investment as part of their collaboration on SC451, an iPSC-derived islet cell therapy for type 1 diabetes. The company also announced positive clinical results at 14 months in UP421 trials and expects to begin Phase 1 trials for both SC451 and SG293 later this year. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $SANA